Menu
Search
|

Menu

Close
X

Tocagen Inc TOCA.OQ (NASDAQ Stock Exchange Global Select Market)

8.83 USD
-- (--)
As of Jun 22
chart
Previous Close 8.83
Open --
Volume --
3m Avg Volume 34,043
Today’s High --
Today’s Low --
52 Week High 14.96
52 Week Low 8.64
Shares Outstanding (mil) 19.81
Market Capitalization (mil) 206.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.647
FY17
-2.093
FY16
-1.809
FY15
-1.246
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
4,809.55
5.71
Price to Book (MRQ)
vs sector
2.34
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
15.95
16.46
LT Debt to Equity (MRQ)
vs sector
7.82
12.19
Return on Investment (TTM)
vs sector
--
14.38
Return on Equity (TTM)
vs sector
--
16.08

EXECUTIVE LEADERSHIP

Faheem Hasnain
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Martin Duvall
Chief Executive Officer, Director, Since 2016
Salary: $67,692.00
Bonus: $24,000.00
Mark Foletta
Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Harry Gruber
President - Science and Innovation, Director, Since 2017
Salary: $355,796.00
Bonus: $25,000.00
Dennis Berman
Executive Vice President - Corporate Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3030 Bunker Hill St Ste 230
SAN DIEGO   CA   92109-5757

Phone: +1858.4128400
Site: tocagen.com

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

SPONSORED STORIES